Meeting
2021 ASCO Annual Meeting
Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma.
Authors
Louis B. Nabors
University of Alabama at Birmingham, Birmingham, AL
Louis B. Nabors , Lawrence S. Lamb Jr., Melissa Jo Beelen , Thriumaine Pillay , Mariska ter Haak , Samantha Youngblood , Louis Vaickus , Mina Lobbous
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT04165941
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2057)
DOI
10.1200/JCO.2021.39.15_suppl.2057
Abstract #
2057
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase I study of drug-resistant immunotherapy (DRI) with gene-modified autologous γδ T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).
First Author: Louis B. Nabors
Poster
2019 ASCO Annual Meeting
Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
First Author: Warren P. Mason
Poster
2019 ASCO Annual Meeting
EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.
First Author: Patrick Roth
Poster
2018 ASCO Annual Meeting
Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
First Author: Frank Saran